Page 459 - Williams Hematology ( PDFDrive )

434 Part V: Therapeutic Principles Chapter 28: Therapeutic Apheresis: Indications, Efficacy, and Complications 435

ADVERSE EFFECTS OF EXTRACORPOREAL 30. Johnson WJ, Kyle RA, Pineda AA, O’Brien PC, et al: Treatment of renal failure asso-
PHOTOCHEMOTHERAPY ciated with multiple myeloma. Plasmapheresis, hemodialysis and chemotherapy. Arch
Intern Med 150:863, 1990.
31. Clark WF, Stewart AK, Rock GA, et al: Plasma exchange when myeloma presents as
Adverse effects are largely related to volume shifts that result in hypoten- acute renal failure. A randomized, controlled trial. Ann Intern Med 143:777, 2005.
sion, which can be managed by pausing the procedure and/or adminis- 32. Gertz MA: Managing myeloma kidney. Ann Intern Med 143:835, 2005.
tering fluids. Transient fevers to 38°C to 39°C have been observed 6 to 33. George JN: Thrombotic thrombocytopenic purpura. N Engl J Med 354:1927, 2006.
8 hours after reinfusion of the treated mononuclear cells. 127 34. Tsai HM: Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med
57:419, 2006.
35. Furlan M, Robles R, Galbusera M, et al: Von Willebrand factor-cleaving protease in
thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J
Med 339:1578, 1998.
REFERENCES 36. Tsai HM, Lian EC: Antibodies to von Willebrand factor-cleaving protease in acute
thrombotic thrombocytopenic purpura. N Engl J Med 339:1585, 1998.
1. Abel JJ, Rowntree LG, Turner BB: Plasma removal with return of corpuscles (plasma- 37. Levy GG, Nichols WC, Lian EC, et al: Mutations in a member of the ADAMTS gene
pheresis). J Pharmacol Exp Ther 5:625, 1914. family cause thrombotic thrombocytopenic purpura. Nature 413:488, 2001.
2. Schwab PJ, Fahey JL: Treatment of Waldenström’s macroglobulinemia by plasmaphere- 38. Rock GA, Shumak KH, Buskard NA, et al: The Canadian apheresis Study Group.
sis. N Engl J Med 263:574, 1960. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic
3. Solomon A, Fahey JL: Plasmapheresis therapy in macroglobulinemia. Ann Intern Med thrombocytopenic purpura. N Engl J Med 325:393, 1991.
58:789, 1963. 39. Henon P: Treatment of thrombotic thrombopenic purpura. Results of a multicenter
4. Schwartz J, Winters JL, Padmanabhan A, et al: Guidelines on the use of therapeutic randomized clinical study. Presse Med 20:1761, 1991.
apheresis in clinical practice—Evidence-based approach from the Writing Committee 40. Sarode R, Bandarenko N, Brecher ME, et al: Thrombotic thrombocytopenic purpura:
of the American Society for Apheresis: The sixth special issue. J Clin Apher 28:145, 2012 American Society for Apheresis (ASFA) consensus conference on classification,
2013. diagnosis, management, and future research. J Clin Apher 29:148, 2014.
5. Guyatt GH, Oxman AD, Vist GE, et al: GRADE: An emerging consensus on rating 41. Zakarija A, Kwaan HC, Moake JL, et al: Ticlopidine- and clopidogrel-associated throm-
quality of evidence and strength of recommendations. Br Med J (Clin Res Ed) 336:924, botic thrombocytopenic purpura (TTP): Review of clinical, laboratory, and epidemi-
2008. ological and pharmacovigilance findings (1989–2008). Kidney Int 75(Suppl 112):S20,
6. AMA RUC Database 2014 version 2. 2009.
7. Weinstein R: Basic principles of therapeutic blood exchange, in Apheresis: Principles 42. Tsai H-M, Rice L, Sarode R, et al: Antibody inhibitors to von Willebrand factor metal-
and Practice, 3rd ed, edited by BC McLeod, R Weinstein, JL Winters, AM Szczepi- loproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-
orkowski, p 269. AABB Press, Bethesda, MD, 2010. associated thrombotic thrombocytopenic purpura. Ann Intern Med 132:794, 2000.
8. Kiss JE: Therapeutic plasma exchange in hematologic diseases and dysproteinemias, 43. Sutton DMC, Nair RC, Rock G: Complications of plasma exchange. Transfusion 29:124,
in Apheresis: Principles and Practice, 3rd ed, edited by BC McLeod, R Weinstein, JL 1989.
Winters, AM Szczepiorkowski, p 319. AABB Press, Bethesda, MD, 2010. 44. Couriel D, Weinstein R: Complications of plasma exchange: A recent assessment. J Clin
9. McLeod BC: Therapeutic plasma exchange, in Rossi’s Principles of Transfusion Medicine, Apher 9:1, 1994.
4th ed, edited by TL Simon, EL Snyder, BG Solheim, CP Stoell, RG Strauss, M Petrides, 45. Weinstein R: Hypocalcemic toxicity and atypical reactions in therapeutic plasma
p 629. Blackwell Publishing, Chichester, UK, 2009. exchange. J Clin Apher 16:210, 2001.
10. McGrath MA, Penny R: Paraproteinemia. Blood hyperviscosity and clinical manifesta- 46. Goss, GA, Weinstein, R: Pentastarch as partial replacement for therapeutic plasma
tions. J Clin Invest 58:1155, 1976. exchange: Effect on plasma proteins, adverse events during treatment, and serum ion-
11. Somer T, Meiselman HJ: Disorders of blood viscosity. Ann Med 25:31, 1993. ized calcium. J Clin Apher 14:114, 1999.
12. Kwaan HC, Bongu A: The hyperviscosity syndromes. Semin Thromb Hemost 25:199, 47. McLeod BC, Sniecinski I, Ciavarella D, Owen H, et al: Frequency of immediate adverse
1999. effects associated with therapeutic apheresis. Transfusion 39:282, 1999.
13. Weinstein R, Mahmood M: Case records of Massachusetts General Hospital. Weekly 48. Shaz BH: Red cell exchange and other therapeutic alterations of red cell mass, in Apher-
clinicopathological exercises. Case 6-2002. A 54-year-old woman with left, then right, esis: Principles and Practice, 3rd ed, edited by BC McLeod, R Weinstein, JL Winters, AM
central-retinal-vein occlusion. N Engl J Med 346:603, 2002. Szczepiorkowski, p 391. AABB Press, Bethesda, MD, 2010.
14. Bloch KJ, Maki DG: Hyperviscosity syndromes associated with immunoglobulin 49. Swerdlow PS: Red cell exchange in sickle cell disease. Hematology Am Soc Hematol Educ
abnormalities. Semin Hematol 10:113, 1973. Program 48, 2006.
15. Capra JD, Kunkel HG: Aggregation of gammaG3 proteins: Relevance to the hypervis- 50. Kernoff LM, Botha MC, Jacobs P: Exchange transfusion in sickle cell disease using a
cosity syndrome. J Clin Invest 49:610, 1970. continuous-flow blood cell separator. Transfusion 17:269, 1977.
16. Fahey JL, Barth WF, Solomon A: Serum hyperviscosity syndrome. JAMA 192:464, 51. Klein HG, Garner RJ, Miller DM, et al: Automated partial exchange transfusion in
1965. sickle cell anemia. Transfusion 20:578, 1980.
17. Beck JR, Quinn BM, Meier FA, Rawnsley HM: Hyperviscosity syndrome in parapro- 52. Nadler SB, Hidalgo JU, Bloch T: Prediction of blood volume in normal human adults.
teinemia managed by plasma exchange, monitored by serum tests. Transfusion 22:51, Surgery 51:224; 1962.
1982. 53. Division of Blood Diseases and Resources: The Management of Sickle Cell Disease, 4th ed.
18. Chopek M, McCullough J: Protein and biochemical changes during plasma exchange, NIH Publication No. 02-2117. NHLBI, Bethesda, MD, 2002.
in Therapeutic Hemapheresis, edited by EM Berkman, J Umlas, p 13. AABB Press, 54. Steinberg MH: Management of sickle cell disease. N Engl J Med 340:1021, 1999.
Washington, DC, 1980. 55. Platt OS: Prevention and management of stroke in sickle cell anemia. Hematology Am
19. Stone MJ, Bogen SA: Evidence-based focused review of management of hyperviscosity Soc Hematol Educ Program 54, 2006.
syndrome. Blood 119:2205, 2012. 56. Weinstein R: Specialized therapeutic hemapheresis and phlebotomy, in Rossi’s Principles
20. Brouet J-C, Clauvel J-P, Danon F, et al: Biologic and clinical significance of cryoglobu- of Transfusion Medicine, 4th ed, edited by TL Simon, EL Snyder, BG Solheim, CP Stow-
lins. A report of 86 cases. Am J Med 57:775, 1974. ell, RG Strauss, M Petrides, p 652. AABB Press, Bethesda, MD, 2009.
21. Ferri C, Zignego AL, Pileri SA: Cryoglobulins. J Clin Pathol 55:4, 2002. 57. Kim HC, Dugan NP, Silber JH et al: Erythrocytapheresis therapy to reduce iron over-
22. Ferri C, Moriconi L, Gremignai G, et al: Treatment of the renal involvement of mixed load in chronically transfused patients with sickle cell disease. Blood 83:1136, 1994.
cryoglobulinemia with prolonged plasma exchange. Nephron 43:246, 1986. 58. Hilliard LM, Williams BF, Lounsbury AE: Erythrocytapheresis limits iron accumula-
23. Berkman EM, Orlin JB: Use of plasmapheresis and partial plasma exchange in the man- tion in chronically transfused sickle cell patients. Am J Hematol 59:28, 1998.
agement of patients with cryoglobulinemia. Transfusion 20:171, 1980. 59. Singer ST, Quirolo, Nishi K: Erythrocytapheresis for chronically transfused children
24. Shaw M, Van de Pette J, Fenton D, McGibbon DH: Mutilating cryoglobulinemia rapidly with sickle cell disease: An effective method for maintaining a low hemoglobin S level
improved by plasmapheresis: Diagnostic features on blood film. J R Soc Med 78(Suppl 11): and reducing iron overload. J Clin Apher 14:122, 1999.
37, 1985. 60. Sarode R1, Matevosyan K, Rogers ZR, et al: Advantages of isovolemic hemodilution-red
25. Goldschmidt H, Lannert H, Brommer J, Ho AD: Multiple myeloma and renal failure. cell exchange therapy to prevent recurrent stroke in sickle cell anemia patients. J Clin
Nephrol Dial Transplant 15:301, 2000. Apher 26:200, 2011.
26. Feest TG, Burge PS, Cohen SL: Successful treatment of myeloma kidney by dieresis and 61. Turner JM, Kaplan JB, Cohen HW, Billett HH: Exchange versus simple transfusion for
plasmapheresis. Br Med J 1:503, 1976. acute chest syndrome in sickle cell anemia adults. Transfusion 49:863, 2009.
27. Misiani R, Remuzzi G, Bertani T, Licini R, et al: Plasmapheresis in the treatment of 62. Trampuz A, Jereb M, Muzlovic I, Prabhu RM: Clinical review: Severe malaria. Crit Care
acute renal failure in multiple myeloma. Am J Med 66:684, 1979. 7:315, 2003.
28. Zucchelli P, Pasquali S, Cagnoli L, Rovinetti C: Plasma exchange in acute renal failure 63. Severe falciparum malaria. World Health Organization, Communicable Diseases Clus-
due to light chain myeloma. Trans Am Soc Artif Intern Organs 30:36, 1984. ter. Trans R Soc Trop Med Hyg 84(Suppl 1):S1, 2000.
29. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G: Controlled plasma exchange trial in acute 64. Centers for Disease Control and Prevention: CDC Treatment Guidelines: Treatment of
renal failure due to multiple myeloma. Kidney Int 33:1175, 1988. Malaria (Guidelines or Clinicians). CDC, Atlanta, GA, 2009.

Kaushansky_chapter 28_p0427-0436.indd 434 9/17/15 6:05 PM